Results 181 to 190 of about 32,524 (285)

Bone Health Following Lifestyle‐Induced Weight Loss in Individuals With Overweight/Obesity: A Narrative Review

open access: yesObesity, EarlyView.
ABSTRACT Although weight loss has many health benefits for people with overweight/obesity, its potential negative impact on bone health needs to be considered. This review provides a comprehensive overview of the effects of intentional weight loss achieved by lifestyle changes on bone health outcomes in adults with overweight/obesity and discusses ...
Mélanie A. Legrand   +7 more
wiley   +1 more source

Analysis glycemic variability in pregnant women with various type of hyperglycemia. [PDF]

open access: yesBMC Pregnancy Childbirth
Zhou X, Zhang R, Jiang S, Cheng D, Wu H.
europepmc   +1 more source

Glucose‐Dependent Insulinotropic Polypeptide and Glucagon After Weight Loss Induced by Diet or Bariatric Surgery

open access: yesObesity, EarlyView.
ABSTRACT Objective This study compared the effects of a very low‐energy diet (VLED), alone or combined with sleeve gastrectomy (SG) or Roux‐en‐Y gastric bypass (RYGB), on glucose‐dependent insulinotropic polypeptide (GIP) and glucagon concentrations, hormones likely to play a role in weight loss maintenance.
Amanda Finn   +4 more
wiley   +1 more source

Electrochemical and Nanomaterial‐Based Strategies for Nonenzymatic Glucose Detection: A Review

open access: yesChemistryOpen, EarlyView.
This review critically evaluates emerging nonenzymatic glucose sensing platforms, smartphone‐integrated devices, and fifth‐generation strategies for continuous noninvasive glucose monitoring. Electrochemical glucose sensing technologies have undergone significant evolution, with continual advancements aimed at improving sensitivity, selectivity, and ...
Reagan Aviha, Gymama Slaughter
wiley   +1 more source

A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules

open access: yesCPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Dulaglutide, a long‐acting glucagon‐like peptide‐1 (GLP‐1) receptor agonist, is approved for improving glycemic control and reducing cardiovascular risks in patients with type 2 diabetes mellitus (T2DM). This research investigates the effect of dulaglutide on gastric emptying and its impact on the pharmacokinetics (PK) of orally administered ...
Maria M. Posada   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy